BioReference broadens CV test access:
This article was originally published in Clinica
LipoScience has provided BioReference Laboratories with access to its NMR LipoProfile test, so that the latter can use the technology in its new Advanced Cardiovascular Testing (ACT) programme. ACT is aimed at providing comprehensive cardiovascular reports, and will utilise the LipoProfile, which uses NMR spectroscopy to analyse blood plasma samples and inform doctors on the amount of low-density lipoprotein (LDL) particles present. LDL particles transport cholesterol from the liver, and are an indicator of potential heart disease and atherosclerosis levels. This collaboration is in line with LipoScience's goal of broadening the access of the LipoProfile test.
You may also be interested in...
Manufacturers of endoscopic equipment, biofeedback devices and thermometers were among those cited for regulatory violations in US FDA warning letters this week. A total of four device-related enforcement missives were released by the agency.
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.
A flurry of US biosimilar launches over the past few months has opened several molecules to true, multi-source competition, with a range of pricing strategies seen from competitors. However, some brands that already face biosimilar competition elsewhere in the world are still poised to enjoy a significant period of exclusivity in the US, such as AbbVie’s Humira.